Nuvectis Pharma, Inc.
NVCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875558
In the last 90 days, Nuvectis Pharma, Inc. insiders filed 2 open-market purchases and 0 sales; 82 institutions reported holding it in 13F filings for Q2 2026, worth $189.0M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Nuvectis Pharma, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- +3 vs. Q1 2022
- Shares held
- 643.0K
- +14.9K (+2.4%) vs. Q1 2022
- Total value
- $7.20M
- +$2.55M (+54.7%) vs. Q1 2022
- New holders
- 5
- 2 more added
- Sold out
- 2
- 4 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NVCT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 82 | $189.0M |
| Q1 2026 | 62 | $34.9M |
| Q4 2025 | 48 | $32.0M |
| Q3 2025 | 53 | $22.2M |
| Q2 2025 | 47 | $24.2M |
| Q1 2025 | 33 | $20.0M |
| Q4 2024 | 31 | $7.15M |
| Q3 2024 | 31 | $6.60M |
| Q2 2024 | 41 | $7.63M |
| Q1 2024 | 40 | $12.8M |
| Q4 2023 | 36 | $12.6M |
| Q3 2023 | 33 | $16.5M |
| Q2 2023 | 37 | $20.0M |
| Q1 2023 | 13 | $6.34M |
| Q4 2022 | 11 | $7.38M |
| Q3 2022 | 12 | $10.0M |
| Q2 2022 | 11 | $7.20M |
| Q1 2022 | 8 | $4.65M |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Nuvectis Pharma, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ronit Capital LLP | 419,282 | $4.70M | 7.06% | −130,718−23.8% | Reduced |
| Baldwin Brothers Inc | 121,000 | $1.35M | 0.18% | +121,000 | New |
| Citadel Advisors LLC | 35,069 | $393.0K | 0.00% | +35,069 | New |
| Geode Capital Management, LLC | 23,967 | $268.0K | 0.00% | +9,145+61.7% | Added |
| Vanguard Group Inc | 23,257 | $261.0K | 0.00% | +23,257 | New |
| State Street Corp | 11,700 | $131.0K | 0.00% | +11,700 | New |
| BlackRock Inc. | 7,198 | $80.0K | 0.00% | −674−8.6% | Reduced |
| Tower Research Capital LLC (TRC) | 1,279 | $14.0K | 0.00% | −471−26.9% | Reduced |
| Morgan Stanley | 200 | $2.00K | 0.00% | +200 | New |
| UBS Group AG | 62 | $1.00K | 0.00% | −79−56.0% | Reduced |
| Wells Fargo & Company | 21 | $0 | 0.00% | +1+5.0% | Added |
| Millennium Management LLC | 0 | $0 | 0.00% | −42,160−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −11,365−100.0% | Sold out |